ストックスクリーナーアプリを入手
20.09
3.55%
-0.74
前日終値:
$20.83
開ける：
$21.23
24時間の取引高:
129.29K
Relative Volume:
0.51
時価総額：
$353.89M
収益：
$116.88M
当期純損益:
$-25.09M
株価収益率:
-143.50
EPS:
-0.14
ネットキャッシュフロー:
$-20.74M
1週間 パフォーマンス:
-6.86%
1か月 パフォーマンス:
-7.89%
6か月 パフォーマンス:
+60.46%
1年 パフォーマンス:
+79.37%
1日の値動き範囲:
$20.09
$21.37
1週間の範囲:
$20.09
$21.93
52週間の値動き範囲:
$7.4843
$29.82
Rigel Pharmaceuticals Stock (RIGL) Company Profile
名前
Rigel Pharmaceuticals
セクター
電話
650-624-1100
住所
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
RIGL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
20.09 | 353.89M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-04-03 | 再開されました | Piper Sandler | Neutral |
| 2022-06-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-06-08 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 開始されました | B. Riley Securities | Neutral |
| 2020-11-09 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 再開されました | JP Morgan | Overweight |
| 2019-03-01 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 開始されました | Citigroup | Buy |
| 2018-05-02 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 再開されました | Piper Jaffray | Overweight |
| 2017-12-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 再開されました | H.C. Wainwright | Buy |
| 2017-03-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-30 | 繰り返されました | Piper Jaffray | Overweight |
| 2016-07-13 | 開始されました | H.C. Wainwright | Buy |
| 2016-06-13 | 開始されました | Piper Jaffray | Overweight |
| 2016-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 繰り返されました | Stifel | Buy |
| 2012-11-29 | 開始されました | UBS | Neutral |
| 2012-11-06 | 繰り返されました | Oppenheimer | Outperform |
| 2012-03-26 | 開始されました | Canaccord Genuity | Hold |
| 2010-12-10 | ダウングレード | MP Advisors | Outperform → Market Perform |
すべてを表示
Rigel Pharmaceuticals (RIGL) 最新ニュース
Rigel Pharmaceuticals (NASDAQ:RIGL) Share Price Passes Above 200-Day Moving AverageShould You Sell? - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Short Interest Up 22.7% in January - MarketBeat
Thrombocytopenia Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, NDA Approval, Incidence, Therapies, and Companies by DelveInsight - The Globe and Mail
KFDA approves 91 medical products, including rare drug TavalisseCHOSUNBIZ - 조선비즈
Rigel Pharmaceuticals CFO Dean Schorno sells $80,614 in stock - MSN
(RIGL) Technical Pivots with Risk Controls - Stock Traders Daily
Dean L. Schorno Sells 2,036 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Stock - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) CEO Sells $103,595.84 in Stock - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) EVP David A. Santos Sells 2,125 Shares - MarketBeat
Rigel Pharmaceuticals executive Raymond Furey sells $59,652 in stock - MSN
Rigel Pharmaceuticals exec sells shares for $83,836 By Investing.com - Investing.com Nigeria
Rigel Pharmaceuticals exec sells shares for $83,836 - MSN
Rigel Pharmaceuticals executive Raymond Furey sells $59,652 in stock By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals CEO Raul Rodriguez sells shares worth $200,075 By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals CFO Dean Schorno sells $80,614 in stock By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals CEO Raul Rodriguez sells shares worth $200,075 - MSN
CEO, President Rodriguez Raul R sold $200,075 worth of shares (9,352 units at $21.39), decreasing direct ownership by 4% to 239,454 units (SEC Form 4) - Quantisnow
EVP, GC, CCO & Corp Sec Furey Raymond J. sold $59,653 worth of shares (2,787 units at $21.40), decreasing direct ownership by 7% to 38,830 units (SEC Form 4) - Quantisnow
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 38% - Simply Wall St
EVP, Chief Commercial Officer Santos David A sold $83,836 worth of shares (3,921 units at $21.38), decreasing direct ownership by 7% to 51,704 units (SEC Form 4) - Quantisnow
BlackRock, Inc. Expands Stake in Rigel Pharmaceuticals Inc - GuruFocus.com
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Short Interest Down 43.4% in January - MarketBeat
Does Rigel (RIGL) Have the Potential to Rally 40.88% as Wall Street Analysts Expect? - MSN
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $36.20 Average Target Price from Analysts - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $36.20 Consensus PT from Brokerages - Defense World
When (RIGL) Moves Investors should Listen - Stock Traders Daily
JPMorgan Chase & Co. Purchases 8,140 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Investor Network: Rigel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Rigel Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017 - Marketscreener.com
Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis - MarketBeat
Rigel Pharmaceuticals' SWOT analysis: diverse portfolio fuels growth, stock faces headwinds - Investing.com Australia
Rigel's fostamatinib enters Phase 1 trial for sickle cell treatment - MSN
Rigel enrols first subject in Phase I sickle cell disease therapy trial - Clinical Trials Arena
Cantor Fitzgerald Estimates RIGL FY2025 Earnings - Defense World
Rigel Pharmaceuticals' (RIGL) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease - Marketscreener.com
Rigel's fostamatinib enters Phase 1 trial for sickle cell treatment By Investing.com - Investing.com Australia
Rigel Pharmaceuticals enrolls first patient in Phase 1 study of fostamatinib - TipRanks
Equities Analysts Offer Predictions for RIGL FY2025 Earnings - MarketBeat
Rigel Pharmaceuticals (RIGL) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):